I would predict that it depends on where the money is coming from.
For VC firms that are experienced in the biomedical space, Theranos changes nothing because they were already suspicious of Theranos.
For firms that are inexperienced in the biomedical space, they have hopefully learned that growth cannot compensate for flaws in science or technology. If they continue to invest in biomedical, they will be much more careful in their DD; or perhaps they lose their appetite for biomedical and leave entirely.
I don't think things have changed for biomedical startups that are based on good science and technology and have an experienced team.
What would be wonderful is if the media learned a lesson from this mess. As I see it, they were a passenger in the Theranos hype machine.
For VC firms that are experienced in the biomedical space, Theranos changes nothing because they were already suspicious of Theranos.
For firms that are inexperienced in the biomedical space, they have hopefully learned that growth cannot compensate for flaws in science or technology. If they continue to invest in biomedical, they will be much more careful in their DD; or perhaps they lose their appetite for biomedical and leave entirely.
I don't think things have changed for biomedical startups that are based on good science and technology and have an experienced team.
What would be wonderful is if the media learned a lesson from this mess. As I see it, they were a passenger in the Theranos hype machine.